Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41.
A synthetic peptide, corresponding to the sequence (637-666) of the HIV-1 glycoprotein gp41, inhibited the replication of an array of HIV-1 strains. The peptide (637-666) selectively binds to the fusion domain at the N-terminus of gp41, suggesting that inhibition of HIV-1 infection is caused by blocking fusion of HIV-1 with cells or of infected cells with uninfected cells. Since this peptide has antiviral activity against both homologous and heterologous HIV-1 isolates and has no detectable cytotoxicity, it offers a novel approach to chemotherapy and prophylaxis of AIDS.
New York Blood Center, NY 10021.
S
S
Jiang
K
K
Lin
N
N
Strick
A R
AR
Neurath
D000595:Amino Acid Sequence; D001665:Binding Sites; D002460:Cell Line; D015686:Gene Products, env / Q000378:metabolism; D019302:HIV Envelope Protein gp160; D015700:HIV Envelope Protein gp41 / Q000378:metabolism*; D015497:HIV-1 / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D007106:Immune Sera / Q000494:pharmacology; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D010455:Peptides / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D011498:Protein Precursors / Q000378:metabolism; D014779:Virus Replication / Q000187:drug effects*
D015686:Gene Products, env; D019302:HIV Envelope Protein gp160; D015700:HIV Envelope Protein gp41; D007106:Immune Sera; D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors